MedPlus Health Services LimitedQ1 FY27 Results & Financial Update
MedPlus Health Services Limited: Q1 FY27 consolidated results and company financials – revenue ₹1,879.60 Cr, PAT ₹33.17 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
MedPlus Health Services price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore MedPlus Health Services Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
MedPlus Health Services Limited posted consolidated financial results for the first quarter of fiscal year 2027, covering the period ended 30 June 2026. The company reported revenue from operations of INR 1,879.60 crore for the quarter.
Total income for the period stood at INR 1,899.43 crore, which includes other income of INR 19.83 crore. The business operated with minimal finance costs of INR 0.005 crore, reflecting negligible debt financing burdens during the quarter.
Profit before tax (PBT) for Q1 FY27 was recorded at INR 41.88 crore after accounting for depreciation and amortisation expenses of INR 77.92 crore. Tax expenses for the quarter amounted to INR 8.71 crore.
Consolidated profit after tax (PAT) reached INR 33.17 crore, resulting in a basic and diluted earnings per share (EPS) of INR 2.76 for the quarter. The resulting profit-after-tax margin stood at approximately 1.76% of total revenue.
The comparative financial metrics for the prior quarter (Q4 FY26) and the corresponding previous year quarter (Q1 FY26) are not available in the current verified primary XBRL filing snapshot, making sequential and annual growth percentages non-applicable.
Depreciation charges formed a notable component of quarterly overheads at INR 77.92 crore, reflecting ongoing investments in store infrastructure, leasehold improvements, and retail technology systems across the network.
Medplus Health Services Limited reported consolidated revenue from operations of INR 1,879.60 crore for the quarter ended 30 June 2026 (Q1 FY27). Total income for the period stood at INR 1,899.43 crore, which includes other income of INR 19.83 crore.
Profit before tax (PBT) for the quarter was recorded at INR 41.88 crore, after accounting for total expenses, a depreciation and amortisation charge of INR 77.92 crore, and a minimal finance cost of INR 0.005 crore.
01 · Business model
What does MedPlus Health Services do?
MedPlus Health Services Limited operates as a pharmacy retailer in India, offering a wide array of pharmaceutical, medical, and fast-moving consumer goods (FMCG) products through its extensive retail store network.
The company's primary business model relies on a dense footprint of neighbourhood retail stores complemented by an omni-channel delivery infrastructure, serving walk-in retail customers as well as home-delivery orders.
Revenue is generated primarily from the retail sale of medicines, general merchandise, private-label products, and diagnostic services across multiple states and urban centres.
The company's operating leverage is tied closely to store-count expansion, supply-chain efficiency, inventory management, and the ramp-up of newer store cohorts towards operating maturity.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹1,879.60 Cr |
| Total income | ₹1,899.43 Cr |
| Profit before tax | ₹41.88 Cr |
| Profit after tax | ₹33.17 Cr |
| EPS | ₹2.76 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 1.8% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 2.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹19.83 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue is driven by customer footfalls and prescription fulfillments across the company's retail pharmacy chain and digital home-delivery channels.
Total income of INR 1,899.43 crore includes INR 19.83 crore of other income supplementing core operating revenue of INR 1,879.60 crore.
Revenue of INR 1,879.60 crore was generated from core operations, primarily driven by retail store footfall and product sales across the pharmacy and FMCG inventory lines.
Non-operating sources added INR 19.83 crore to the total income pool of INR 1,899.43 crore.
What drove margins
Depreciation and amortisation expenses stood at INR 77.92 crore for the quarter, impacting operating profitability as the store network expands.
Finance costs were minimal at INR 0.005 crore, indicating negligible interest-bearing debt liabilities during the period.
Other income of INR 19.83 crore provided supplementary support to total income, which reached INR 1,899.43 crore.
Total tax provision for the quarter amounted to INR 8.71 crore against a PBT of INR 41.88 crore, establishing the effective tax rate for the period.
04 · Reported developments
What changed operationally
The company maintained positive profitability with a consolidated PAT of INR 33.17 crore and basic EPS of INR 2.76 for Q1 FY27.
05 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Finance costs of INR 0.005 crore indicate that the company maintains an essentially debt-free operational structure during the quarter.
The company reported an extremely low finance cost of INR 0.005 crore for Q1 FY27, indicating negligible formal debt servicing obligations.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory Filing Correction
The company issued a notice requesting stakeholders to ignore an inadvertent investor presentation filing made on 21 July 2026 and refer instead to the subsequently corrected submission.
Reported update
Inadvertent Filing Correction
The company issued a formal retraction notice regarding an inadvertent Investor Presentation attachment filed on 21 July 2026, subsequently replacing it with the correct filing.
07 · Key Q&A
The quarter, answered directly
What does MedPlus Health Services do?
MedPlus Health Services Limited operates as a pharmacy retailer in India, offering a wide array of pharmaceutical, medical, and fast-moving consumer goods (FMCG) products through its extensive retail store network.
What is the clearest takeaway from Q1 FY27?
MedPlus Health Services Limited posted consolidated financial results for the first quarter of fiscal year 2027, covering the period ended 30 June 2026. The company reported revenue from operations of INR 1,879.60 crore for the quarter.
What drove revenue or demand?
Revenue is driven by customer footfalls and prescription fulfillments across the company's retail pharmacy chain and digital home-delivery channels.
What mattered most for margins or profitability?
Depreciation and amortisation expenses stood at INR 77.92 crore for the quarter, impacting operating profitability as the store network expands.
What changed operationally beyond the headline numbers?
The company issued a notice requesting stakeholders to ignore an inadvertent investor presentation filing made on 21 July 2026 and refer instead to the subsequently corrected submission.
What should the next disclosure help confirm?
Monitor future quarterly filings to establish sequential trends once comparative historical data becomes available.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Performance: Monitor future quarterly filings to establish sequential trends once comparative historical data becomes available.
- 02
Store Network Expansion: Track the pace of new store openings and the operational maturation of newer retail cohorts in subsequent disclosures.
- 03
Subsequent Quarterly Financial Performance: Monitor upcoming quarterly disclosures for revenue growth trends and the progression of store-level operational efficiencies.
- 04
Subsequent Financial Disclosures: Future performance will be measured against subsequent quarterly disclosures to establish revenue and profitability growth trajectories.
- 05
Store Network Expansion: Ongoing tracking of store rollout numbers and capital expenditure execution in upcoming reporting periods.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.